Allogeneic versus autologous cell sources present trade-offs in availability, cost, immune risk

https://numberfields.asu.edu/NumberFields/show_user.php?userid=6759483

Allogeneic versus autologous cell sources present trade-offs in availability, cost, immune risk, and standardization that shape clinical strategy and manufacturing.